Eli Lilly plans to introduce its weight-loss pill, orforglipron, in India, offering a non-injectable alternative that may appeal to patients wary of injections. Orforglipron belongs to the GLP-1 drug class, which curbs appetite and mirrors the mechanism of Lilly’s successful injectables Mounjaro and Zepbound. Though not yet approved anywhere globally,...
Eli Lilly Launches Anti-Obesity Drug in India
U.S. drugmaker Eli Lilly & Co. has introduced Mounjaro in India, the country's first treatment of its kind for obesity, with monthly costs ranging from $168 to $210. The medication is approved for weight loss in patients both with and without type-2 diabetes. Industry experts anticipate competition to intensify soon...